Compare iShares Core US Aggregate Bond ETF (AGG) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
iShares Core US Aggregate Bond ETF vs Recursion Pharmaceuticals Inc — how do they compare? iShares Core US Aggregate Bond ETF trades at $97.97, while Recursion Pharmaceuticals Inc trades at $3.68 (market cap $2.04B). The key difference: Recursion Pharmaceuticals Inc is trading nearer its 52-week high, iShares Core US Aggregate Bond ETF nearer its low. Which is the better fit depends on your goals.
| AGG | RXRX | |
|---|---|---|
Sector | Fixed Income | Health |
52-Week High | $101.40 | $6.79 |
52-Week Low | $97.63 | $2.84 |
Market Cap | — | $2.04B |
Enterprise Value | — | $1.46B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AGG trades at $98.65, up 0.04% on the day, with technical indicators showing a bearish trend from moving averages but a neutral signal from oscillators. The stock faces resistance at $99 and support at $98. Recent corporate actions include scheduled dividends for May and June 2026. Financial ratios are unavailable in the provided data, limiting fundamental analysis.
The outlook remains cautious due to the bearish technical bias and lack of current financial metrics. Key risks include market volatility and interest rate uncertainty. Investors should await updated earnings reports for a clearer fundamental picture before considering positions.
RXRX trades at $3.96, up 4.21% today, with a bullish technical signal from moving averages despite overbought RSI readings. The company shows improving quarterly EPS beats but faces deep losses with a -851.51% net margin. Recent news highlights its AI-driven drug discovery platform and inclusion in Cathie Wood's portfolio (The Motley Fool, 2026-07-05).
Analyst consensus is mixed with 40% buy ratings and a $7.83 price target suggesting significant upside, but high cash burn and negative profitability pose substantial risks. Investment appeal hinges on successful clinical advancements offsetting current financial challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About iShares Core US Aggregate Bond ETF
AGG tracks the Bloomberg U.S. Aggregate Bond Index, providing broad exposure to the total U.S. investment-grade bond market. It serves as a core portfolio building block by diversifying across Treasuries, government-related bonds, corporate debt, and mortgage-backed securities.
Read more on AGG →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
